Make An Appointment Make A Payment Event Registration
Make an appointment

Nassim El Hajj, M.D.

Nassim El Hajj, M.D.

Dr Elhajj received his Internal Medicine degree from Staten Island University Hospital, in Staten Island New York, and completed his gastroenterology fellowship at SUNY Downstate Medical Center, Brooklyn, New York. Dr Elhajj joined our practice in 2008.

Office locations

Memorial Medical Office

Practicing since

2008

Certifications

  • USMLE Step I, 1999
  • USMLE Step II, 2000
  • USMLE Step III, 2001
  • Permanent ECFMG Certificate, 2000

National Provider Identifier

1073719688

Licensure

Florida

Communicate with your physician’s staff through My BGC Health.

Professional Clinical Positions

Professional Clinical Positions
2008 - Present Borland-Groover Clinic, P.A. Jacksonville, Florida

Medical Education

Medical Education
1994 - 2000 Faculty of Medical Sciences, Lebanese University
2000 Medical Diploma, Lebanese University

Postgraduate Education

Postgraduate Education
2005 - 2008 Fellow, Gastroenterology and Hepatology, SUNY Downstate Medical Center Brooklyn, New York
2004 - 2005 Chief Medical Resident, Staten Island University Hospital Staten Island, New York
2001 - 2004 Internal Medicine, Staten Island University Hospital Staten Island, New York

Publications

Pegylated interferon-induced immune-mediated hepatitis post-liver transplantation. Liver Transplantation Volume 12, Issue 5, Date: May 2006, Pages: 827-830

The development of DE NOVO autoimmune hepatitis (immune-mediated hepatitis) and its effect on outcome in patients with HCV post liver transplantation. Hepatology, Volume 44, Issue S1 (p 414A), Abstract # 606

Abstracts

The development of DE NOVO autoimmune hepatitis (immune-mediated hepatitis) and its effect on outcome in patients with HCV post liver transplantation. Poster presentation - AASLD meeting - Boston October 2006

The Risk of Acute Rejection in Patients Treated with Pegylated Interferon and Ribavirin for Recurrent Hepatitis C Post Liver Transplantation. Poster presentation - Digestive Disease Week - New Orleans May 2004

Improved Efficacy and Tolerability in Treating Post-Transplant HCV Utilizing an Escalating Regimen of Pegylated Interferon a-2a and Ribavirin with Hematopoietic Growth Factors: A Prospective Study. Oral presentation - Digestive Disease Week - New Orleans May 2004

Switching from Peg-Interferon a-2b to an escalating Peg-Interferon a-2a Regimen for recurrent Hepatitis C Post Liver Transplantation may Improve Virological Response and Tolerability. Poster presentation - Digestive Disease Week - New Orleans May 2004